Use of Statins to Inhibit Inflammation and Vascular Disease
AssigneeMUSC Foundation for Research Development
InventorInderjit Singh
Life of this patent
Estimating the term…
Abstract
The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP.
Claims32
1-75. (canceled)
A method of treatment of a human having above normal inflammation comprising administering a biologically effective amount of an inhibitor of 3-hydroxy-3-Methylglutaryl coenzyme A (HMG-CoA) reductase in order to suppress heart disease.
A method for treating a human, the method comprising:
- selecting the human on the basis that the human is known to exhibit one or more characteristics of inflammation and;
- administering to the human a pharmaceutical composition comprising:
- (a) a biologically effective amount of a HMG CoA reductase inhibitor;
- and
- (b) a pharmaceutically acceptable carrier,
- wherein the composition is orally administered to the human.
A method for reducing risk of stroke or myocardial infarction in a human, the method comprising:
- selecting the human on the basis that the human is known to exhibit one or more characteristics of inflammation and administering to the human a pharmaceutical composition comprising:
- (a) a biologically effective amount of a HMG CoA reductase inhibitor;
- and
- (b) a pharmaceutically acceptable carrier,
- wherein the composition is orally administered to the human.
A method for treating nitric oxide cytotoxicity in a human subject comprising administering to the human a pharmaceutical composition comprising:
- (a) a biologically effective amount of a HMG CoA reductase inhibitor;
- and
- (b) a pharmaceutically acceptable carrier, wherein the inhibitor is orally administered to the human.
A method for treating a subject having inflammation, the method comprising administering to said subject a pharmaceutical composition comprising:
- (a) a biologically effective amount of an HMG CoA reductase inhibitor;
- and
- (b) a pharmaceutically acceptable carrier,
- wherein the inhibitor is orally administered to the human, and where said human does not have hypercholesterolemia and further wherein said administration treats or inhibits the progression of a vascular disease characterized by said inflammation.
A method for treating heart disease or stroke in a subject that has heart disease or stroke or has been identified as being at risk for developing heart disease or stroke wherein said subject has inflammation by administering to the human a pharmaceutical composition comprising:
- (a) a biologically effective amount of a HMG CoA reductase inhibitor;
- and
- (b) a pharmaceutically acceptable carrier, wherein the HMG CoA reductase inhibitor is orally administered to the human.
Dependencies are inferred from the claim text.